See more : China Networks International Holdings, Ltd. (CNWHF) Income Statement Analysis – Financial Results
Complete financial analysis of Cybin Inc. (CYBN.NE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cybin Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Dow Inc. (2OY.DE) Income Statement Analysis – Financial Results
- Western Metals Corporation (WTLC) Income Statement Analysis – Financial Results
- Orvana Minerals Corp. (ORVMF) Income Statement Analysis – Financial Results
- Nine Entertainment Co. Holdings Limited (NNMTF) Income Statement Analysis – Financial Results
- Mahindra & Mahindra Financial Services Limited (M&MFIN.NS) Income Statement Analysis – Financial Results
Cybin Inc. (CYBN.NE)
About Cybin Inc.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 864.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 424.00K | 251.00K | 168.00K | 664.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -424.00K | -251.00K | -168.00K | 200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 23.15% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.36M | 26.15M | 17.59M | 3.30M | 321.60K | 0.00 | 0.00 |
| General & Administrative | 29.80M | 24.49M | 44.79M | 22.48M | 1.36M | 0.00 | 0.00 |
| Selling & Marketing | 2.79M | 881.00K | 1.47M | 4.95M | 117.60K | 0.00 | 0.00 |
| SG&A | 46.47M | 25.37M | 46.25M | 27.42M | 1.63M | 80.52K | 127.22K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -482.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 78.84M | 51.52M | 63.84M | 30.72M | 1.94M | 80.52K | 127.22K |
| Cost & Expenses | 78.84M | 51.52M | 63.84M | 31.39M | 1.94M | 80.52K | 127.22K |
| Interest Income | 619.00K | 603.00K | 241.00K | 60.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 260.00K | 251.00K | 168.00K | 49.00K | 1.95M | 171.86K | 0.00 |
| EBITDA | -78.58M | -47.24M | -63.67M | -32.17M | 9.60K | -100.52K | -127.22K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -3,520.25% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.84M | -54.94M | -63.60M | -30.46M | -1.95M | -80.52K | -127.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -3,525.93% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 756.00K | 4.03M | -3.79M | -1.19M | 9.60K | -20.00K | 4.00 |
| Income Before Tax | -78.08M | -47.49M | -67.63M | -32.22M | -1.94M | -100.52K | -127.22K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.03M | -60.49K | 10.00K | 9.60 | -171.86K | 0.00 |
| Net Income | -78.08M | -47.49M | -67.63M | -32.22M | -1.94M | -100.52K | -127.22K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| EPS | -9.50 | -0.26 | -0.40 | -0.32 | -0.05 | -0.01 | -0.01 |
| EPS Diluted | -9.41 | -0.26 | -0.40 | -0.32 | -0.04 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 8.22M | 185.43M | 167.29M | 100.01M | 40.50M | 13.89M | 13.89M |
| Weighted Avg Shares Out (Dil) | 8.30M | 185.43M | 167.29M | 100.01M | 49.98M | 13.89M | 13.89M |
Source: https://incomestatements.info
Category: Stock Reports